Skip to main content
. 2022 Apr 5;198(1):62–72. doi: 10.1111/bjh.18162

FIGURE 5.

FIGURE 5

Plasma concentration–time profile of zanubrutinib on day 1 of week 2 after multiple doses in Chinese patients with relapsed/refractory B‐cell malignancies